affimed
report
quarter
financial
results
corporate
update
november
heidelberg
germany
november
affimed
nasdaq
afmd
company
committed
giving
patients
back
innate
ability
fight
cancer
announced
today
release
third
quarter
results
tuesday
november
host
conference
call
et
discuss
financial
results
corporate
developments
conference
call
available
via
phone
webcast
access
call
please
dial
callers
international
callers
reference
conference
id
approximately
minutes
prior
call
access
live
audio
webcast
conference
call
please
visit
investors
section
company
website
https
investors
replay
call
archived
affimed
website
days
call
affimed
affimed
nasdaq
afmd
company
committed
giving
patients
back
innate
ability
fight
cancer
affimed
platform
allows
innate
cell
engagers
designed
specific
patient
populations
company
developing
single
combination
therapies
treat
hematologic
solid
tumors
company
currently
enrolling
patients
study
relapsed
refractory
peripheral
cell
lymphoma
phase
dose
escalation
expansion
study
treatment
advanced
solid
tumors
information
please
visit
investor
relations
contact
